Perth biotechnology company Syngenis Labs raises an oversubscribed $4 million ahead of its planned initial public offering. Multiple outlets report the pre-float funding is intended to expand the company’s AI-driven RNA platform and support growth of its genetic medicine capabilities. The reports describe the fundraising as pre-IPO capital that will help Syngenis develop and scale its platform, including efforts to accelerate manufacturing activities aligned with GMP standards. While the articles focus on the technology expansion and domestic capability building, they do not provide detailed information on the timing of the IPO, the size of the eventual float, or specific clinical or commercial milestones. Overall, the sources agree on the key terms of the announcement: the amount raised, the fact that the raise is oversubscribed, and the stated use of proceeds—platform development and manufacturing capability strengthening—within Syngenis’s biotech operations.